Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Expects U.S.-Indian Ties Under Freer Embryonic Stem Cell Policy

This article was originally published in PharmAsia News

Executive Summary

Indian research organizations expect to reap the benefits of the U.S. change in policy to free up federal funds for research using embryonic stem cells. The Indian organizations expect foreign research firms to seek collaboration with Indian companies to conduct the research because of the country's cheaper research and trial costs. India's policy on embryonic stem cell research is close to the new U.S. policy and the genetic versatility of its huge population also is highly attractive. Stem cell research in general is expected to grow about 15 percent in India by 2010. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts